APLS vs. MDGL, IONS, BBIO, OGN, NUVL, ALPN, ALKS, PRGO, CYTK, and BPMC
Should you be buying Apellis Pharmaceuticals stock or one of its competitors? The main competitors of Apellis Pharmaceuticals include Madrigal Pharmaceuticals (MDGL), Ionis Pharmaceuticals (IONS), BridgeBio Pharma (BBIO), Organon & Co. (OGN), Nuvalent (NUVL), Alpine Immune Sciences (ALPN), Alkermes (ALKS), Perrigo (PRGO), Cytokinetics (CYTK), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical preparations" industry.
Madrigal Pharmaceuticals (NASDAQ:MDGL) and Apellis Pharmaceuticals (NASDAQ:APLS) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their community ranking, risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.
Madrigal Pharmaceuticals has a beta of -0.33, suggesting that its stock price is 133% less volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500.
Madrigal Pharmaceuticals has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -79.67%. Apellis Pharmaceuticals' return on equity of -128.60% beat Madrigal Pharmaceuticals' return on equity.
Madrigal Pharmaceuticals received 132 more outperform votes than Apellis Pharmaceuticals when rated by MarketBeat users. Likewise, 68.60% of users gave Madrigal Pharmaceuticals an outperform vote while only 67.37% of users gave Apellis Pharmaceuticals an outperform vote.
Madrigal Pharmaceuticals currently has a consensus price target of $345.09, indicating a potential upside of 54.55%. Apellis Pharmaceuticals has a consensus price target of $76.27, indicating a potential upside of 88.03%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Apellis Pharmaceuticals is more favorable than Madrigal Pharmaceuticals.
In the previous week, Apellis Pharmaceuticals had 6 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 14 mentions for Apellis Pharmaceuticals and 8 mentions for Madrigal Pharmaceuticals. Apellis Pharmaceuticals' average media sentiment score of 0.85 beat Madrigal Pharmaceuticals' score of 0.44 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media.
Madrigal Pharmaceuticals has higher earnings, but lower revenue than Apellis Pharmaceuticals. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Madrigal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 96.3% of Apellis Pharmaceuticals shares are owned by institutional investors. 23.9% of Madrigal Pharmaceuticals shares are owned by insiders. Comparatively, 6.8% of Apellis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Madrigal Pharmaceuticals and Apellis Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks.
Get Apellis Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Apellis Pharmaceuticals Competitors List
Related Companies and Tools
